MYRIAD GENETICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31)
MYRIAD GENETICS, INC. (MYGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) of $40.20 million for the 9-month period ending 2012-03-31, per its 10-Q filed 2012-05-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardCompensationCost · last filed 2012-05-02
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$11.55M.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $5.76M.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $45.99M.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for fiscal 2011 was $807.00K, a 1.94% decline from fiscal 2010.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for fiscal 2010 was $823.00K, a 13.55% decline from fiscal 2009.
- MYRIAD GENETICS, INC. share-based compensation arrangement by share-based payment award, compensation cost (deprecated 2012-01-31) for fiscal 2009 was $952.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | -$11.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-02 | -$5.80M derived: sum of 2 quarters · filed 2012-05-02 | $40.20M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-01 | $51.75M 10-Q · filed 2012-02-01 | ||
| 2011-09-30 | $45.99M 10-Q · filed 2011-11-02 | |||
| 2011-06-30 | $807.00K 10-K · filed 2011-08-15 | |||
| 2010-06-30 | $823.00K 10-K · filed 2011-08-15 | |||
| 2009-06-30 | $952.00K 10-K · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |